Summary

• Revolution Medicines announced at the AACR meeting in San Diego that their drug daraxonrasib showed strong efficacy in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).
• The drug seems to have doubled patients’ expected lifespan (13.2 months overall survival versus 6.7 months for chemotherapy standard of care).
• Daraxonrasib targets the RAS protein, which has been a white whale of oncology for decades.

We have some really interesting progress in pancreatic cancer to talk about, both on the small-molecule and the mRNA vaccine fronts. Let’s do the small-molecule ones first, because those were honestly more unexpected.

So

3.96K Followers